On November 20, 2019, NS Pharma joined Parent Project Muscular Dystrophy for a webinar to provide the community with an overview of its investigational drug, viltolarsen (NS-065/NCNP-01), including its mechanism of action and regulatory status. NS Pharma also provided an update on the viltolarsen clinical program, including the completed Phase 1, Phase 1/2, and Phase 2 studies, as well as an update on the viltolarsen Phase 3 trial (RACER53), including anticipated countries where study will be conducted, study design, description of the endpoints, and inclusion/exclusion criteria.

If you missed the live event, the recording can be found below.

* This webinar recording contains edits to content requested by the company.

Watch the Recording